CAC All-Tradable

ERYTECH Provides Business and Financial Update for the Third Quarter of 2022

Retrieved on: 
Lundi, novembre 21, 2022
Income tax, Lyon, BLA, Patient, ISIN, Q&A, Webcast, CAC Mid 60, CAC All-Tradable, CAC, Sale, Cancer, Princeton University, CMO, Euronext, Pharmaceutical industry, Broadcasting

Income tax included in 2022 a provision of 3.8 million ($4.1 million), reflecting the maximal potential tax impacts of the capital gain from the sale of the Princeton facility.

Key Points: 
  • Income tax included in 2022 a provision of 3.8 million ($4.1 million), reflecting the maximal potential tax impacts of the capital gain from the sale of the Princeton facility.
  • As of September 30, 2022, ERYTECH had cash and cash equivalents totaling 47.3 million (approximately $46.3 million), compared with 33.7 million as of December 31, 2021.
  • ERYTECH management will hold a conference call and webcast on Tuesday, November 22, 2022, at 8:30am ET / 2:30pm CET on the business highlights and financial results for the third quarter of 2022.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Announces Receipt of Nasdaq Notice

Retrieved on: 
Jeudi, octobre 13, 2022
American, CAC All-Tradable, GMP, CAC Mid 60, Patient, 150, CAC, Nasdaq, Cancer, Technology, ISIN, ADSS, Company, Catalent, Letter, Compliance, Pharmaceutical industry, Euronext

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the applicable grace period to regain compliance is 180 days, or until April 5, 2023.

Key Points: 
  • Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the applicable grace period to regain compliance is 180 days, or until April 5, 2023.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Provides Regulatory Update

Retrieved on: 
Mercredi, août 24, 2022
ISIN, BLA, Technology, Cancer, CAC All-Tradable, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, 150, CAC Mid 60, Sale, Society, Food, ALL, American Society of Hematology, Catalent, Neurotransmission, GMP, Fast Track, Nasdaq, Intention, Â, Company, FDA, Biologics license application, Hematology, CAC, Review, Patient, Pharmaceutical industry, Euronext

We are obviously disappointed to stop the process of seeking approval for Graspa in ALL after all the work done and clinical promise observed in this indication, said Gil Beyen, Chief Executive Officer of ERYTECH.

Key Points: 
  • We are obviously disappointed to stop the process of seeking approval for Graspa in ALL after all the work done and clinical promise observed in this indication, said Gil Beyen, Chief Executive Officer of ERYTECH.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

Retrieved on: 
Mardi, mai 24, 2022
Internet, 150, Document, Availability, Company, Medicine, CAC All-Tradable, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Catalent, Food, GMP, Organic acid, Survival, Metabolism, Nasdaq, Director, Annual, European Medicines Agency, Patient, Acute lymphoblastic leukemia, Mass meeting, Combined, Annual general meeting, Shareholder, FDA, Asparaginase, CAC, ISIN, Asparagine, IST, Board, Technology, CAC Mid 60, Adoption, ALL, Le Grand, Pancreatic cancer, Cancer, Growth, Fine chemical, Security (finance), Pharmaceutical industry, Euronext

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

Key Points: 
  • ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
    Cambridge, MA (U.S.) and Lyon (France), May 24, 2022 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 24, 2022.
  • ERYTECHs shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Htel Intercontinental Paris Le Grand, 2 rue Scribe, 75009 Paris (FRANCE).
  • Shareholders have access to the preparatory and information documents for the Shareholders Meeting as provided for by law and the regulations.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Mardi, mai 17, 2022
150, Company, Medicine, CAC All-Tradable, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Catalent, Food, GMP, Organic acid, Survival, Metabolism, European Medicines Agency, CAC Mid 60, Patient, Acute lymphoblastic leukemia, Nasdaq, FDA, Asparaginase, CAC, ISIN, Asparagine, IST, Conference, Technology, ALL, Pancreatic cancer, Cancer, Growth, Pharmaceutical industry, Euronext

The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards.

Key Points: 
  • The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards.
  • For more information on the H.C. Wainwright 23rd Global Investment Conference, please visit the H.C. Wainwright Conference website https://hcwevents.com/globalconference/ .
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Provides Business and Financial Update for the First Quarter of 2022

Retrieved on: 
Jeudi, mai 12, 2022
CEST, Income, 150, Company, R, Medicine, CAC All-Tradable, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Catalent, Food, GMP, Organic acid, Survival, Metabolism, ISIN, CAC Mid 60, Euronext, European Medicines Agency, Webcast, Patient, Acute lymphoblastic leukemia, Nasdaq, FDA, CAC, Asparaginase, Asparagine, IST, Conference, Technology, Marginal cost, Q&A, CMO, ALL, Pancreatic cancer, Cancer, Growth, CEO, Property management, Video game, Pharmaceutical industry

As of March 31, 2022, ERYTECH had cash and cash equivalents totaling 25.1 million (approximately $27.9 million), compared with 33.7 million as of December 31, 2021.

Key Points: 
  • As of March 31, 2022, ERYTECH had cash and cash equivalents totaling 25.1 million (approximately $27.9 million), compared with 33.7 million as of December 31, 2021.
  • The company does not plan to draw any further OCABSA tranche until the expiration of the financing facility in June 2022.
  • ERYTECH management will hold a conference call and webcast on Friday, May 13, 2022, at 8:30am ET / 2:30 pm CEST on the business highlights and financial results for the quarter ended March 31, 2022.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

Retrieved on: 
Jeudi, avril 28, 2022
CAC Mid 60, Medicine, U.S. Securities and Exchange Commission, Euronext Paris, GMP, CAC All-Tradable, AMF, IST, Patient, FDA, Investor, CAC, Pancreatic cancer, Metabolism, Catalent, Cancer, Technology, Organic acid, Growth, Asparaginase, Food, Company, European Medicines Agency, Annual report, Asparagine, Euronext, ISIN, SEC, ALL, 150, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Survival, Nasdaq, Acute lymphoblastic leukemia, Pharmaceutical industry, Renewable energy

These documents can be accessed on the Investors section of the Companys corporate website ( www.erytech.com ).

Key Points: 
  • These documents can be accessed on the Investors section of the Companys corporate website ( www.erytech.com ).
  • In addition, the Universal Registration Document is available on the website of the AMF ( www.amf-france.org ) and the Annual Report on Form 20-F is also available on the website of the SEC ( www.sec.gov ).
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

Retrieved on: 
Lundi, avril 25, 2022
Nasdaq, Catalent, Sale, Cooley LLP, Patient, European Medicines Agency, Technology, FDA, Acquisition, 150, CAC All-Tradable, CAC Mid 60, DNA, CDMO, Food, TILS, Employment, IST, Company, Asparaginase, Euronext Paris, Partnership, Acute lymphoblastic leukemia, LLP, Medicine, Asparagine, CAC, Pancreatic cancer, APA, ALL, GMP, Growth, ISIN, NKS, Industry, BLA, Euronext, Therapy, Organic acid, Cancer, Survival, Microsoft, Potyvirus, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AAV, Metabolism, TCR, Pharmaceutical industry, Security (finance), Fine chemical, Princeton University

Under the terms of an asset purchase agreement between ERYTECH and Catalent (the APA), Catalent agreed to acquire ERYTECHs state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total consideration of $44.5 million.

Key Points: 
  • Under the terms of an asset purchase agreement between ERYTECH and Catalent (the APA), Catalent agreed to acquire ERYTECHs state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total consideration of $44.5 million.
  • ERYTECHs Princeton facility is a 30,900 sqft cutting edge manufacturing facility, designed with the flexibility to expand to support various cell therapy production requirements and capacities.
  • ERYTECH will retain its manufacturing site in Lyon, France and its expertise and capabilities in manufacturing process science to continue innovating in cell therapy manufacturing.
  • The parties will also enter into a long-term supply agreement for the manufacturing and supply of the lead product candidate eryaspase (GRASPA) by Catalent to ERYTECH.

ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology

Retrieved on: 
Mercredi, avril 6, 2022
IST, CAC All-Tradable, CAC, Asparaginase, European Medicines Agency, Medicine, ISIN, Technology, Asparagine, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GMP, Pancreatic cancer, 150, Wiley, CAC Mid 60, Hypersensitivity, Metabolism, Allergy, Principal investigator, Organic acid, Growth, Survival, Nordic Society for Middle Eastern Studies, ALL, FDA, Patient, Company, British Journal of Haematology, Bone marrow, Paper, Associate, Cancer, Food, Acute lymphoblastic leukemia, Safety, Aarhus University Hospital, PHASE 2, Blood, Pharmaceutical industry, Medical imaging, Red blood cell, Euronext

The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological profile of eryaspase in ALL patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.

Key Points: 
  • The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological profile of eryaspase in ALL patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.
  • Eryaspase demonstrated sustained asparaginase enzyme activity above the threshold of >100 U/L at trough levels 14 days after first infusion in 92.5% of patients.
  • The Principal Investigator, Dr. Birgitte Klug Albertsen, Associate Professor at Aarhus University Hospital, Denmark, commented, "I am grateful that the editors of the British Journal of Haematology selected our study for publication.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society

Retrieved on: 
Lundi, avril 4, 2022
IST, Company, CAC All-Tradable, Metabolism, Red blood cell, Carrier, CAC, Organic acid, Growth, ERCS, Asparaginase, European Medicines Agency, TM, Survival, Time zone, Program, Cancer, Medicine, CEO, Food, ISIN, Acute lymphoblastic leukemia, ALL, Seminal vesicles, 150, Technology, Asparagine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, GMP, FDA, RBC, CAC Mid 60, Pancreatic cancer, Patient, Fine chemical, Vaccine, Pharmaceutical industry, Euronext

Oral presentation: Evaluation of production methods, characterization and biological activity of RBC-derived extracellular vesicles (RBCEVs) containing active molecules.

Key Points: 
  • Oral presentation: Evaluation of production methods, characterization and biological activity of RBC-derived extracellular vesicles (RBCEVs) containing active molecules.
  • Vesiculation of RBCs that have already been loaded with active therapeutic compounds utilizing the ERYCAPS process, entails the potential of producing cargo-loaded RBC-derived extracellular vesicles for the development of novel therapeutic approaches.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.